newsfilter
← Latest News
PR Newswire·

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

HELPACHCJNJBWAYAIFF
  • The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from approximately $1.8 billion in 2023 to $4.26 billion by 2033, representing a 9% annual growth rate.
  • Broader anxiety treatment market estimates suggest a potential value of $12 billion to $17+ billion within the next decade.
  • Helus Pharma announced statistically significant results from a Phase 2 signal detection study for HLP004, showing a mean 10.4-point reduction in HAM-A scores (p<0.0001) when used adjunctively with standard care.
  • HLP004 demonstrated durable effects at six months, with 67% of the pooled study population classified as responders and 39% in remission.
  • The treatment showed acute effects lasting approximately 90 minutes, with most Phase 1 participants ready for discharge within three hours, and no drug-related serious adverse events were recorded.
  • Acadia Healthcare reported Q4 2025 revenue of $821.5 million, a 6.1% increase year-over-year, though the company reported a net loss of $13.02 per diluted share due to a $996.2 million non-cash goodwill impairment charge.
  • Johnson & Johnson announced that 11 abstracts on its neuropsychiatry portfolio, including research on depression, will be presented at the 64th Annual Meeting of the American College of Neuropsychopharmacology.
  • BrainsWay unveiled data showing its SWIFT accelerated Deep TMS protocol achieves comparable remission rates to traditional methods while reducing the acute treatment phase from 20 visits to just 6 half-days.
  • Firefly Neuroscience reported a 20-fold expansion in commercial footprint and a 33-fold increase in EEG/ERP scan volumes, driven by the acquisition of Evoke Neuroscience.
  • Market News Updates (MNU) disclosed it received $4,600 from Helus Pharma for news coverage but holds no shares of any company mentioned in the release.